Murine model of FLT3-ITD and IDH2 co-mutated AML showed that enasidenib treatment significantly reduced 2-HG levels and induced demethylation of hypermethylated CpG islands, but enasidenib alone was not enough to suppress the malignant clones. The gene discussed is IDH2; the disease is acute myeloid leukemia.